Arcus Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $2.79B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 27, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | During market hours | $41.00M | $-0.72 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | During market hours | $17.00M | $-1.02 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | During market hours | $33.00M | $-0.89 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 28, 2025 | During market hours | $26.00M | $-1.27 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | $160.00M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | During market hours | $28.00M | $-1.14 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | During market hours | $36.00M | $-1.03 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | $48.00M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 21, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| cash | end 2026 | $600.00M | New |
| GAAP revenueGAAP | full year 2026 | $65.00M to $75.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Arcus Biosciences filed with the SEC
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
GILEAD AND ARCUS ANNOUNCE AMENDED COLLABORATION AND EQUITY INVESTMENT
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update
Results of operations · EX-99 to Form 8-K
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update
Results of operations · EX-99 to Form 8-K
Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update
Results of operations · EX-99.1 to Form 8-K
Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study
Results of operations · EX-99.1 to Form 8-K